Skip to content
OpenCapital
Get started

Kiniksa Pharmaceuticals International, plc KNSA Debt-to-assets

Debt-to-assets at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
0×0.0×
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
0.1×-0.1×
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
0×0.0×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
0×—
MoonLake Immunotherapeutics logo
MoonLake ImmunotherapeuticsMLTX
0.3×+0.1×
BridgeBio Pharma logo
BridgeBio PharmaBBIO
2.4×+2.4×

Other financials

Income statement

See full
Revenue$214.3M+55.5%
Gross profit$193.5M+61.3%
Operating income$29.3M+121%
Net income$22.6M+165%
EPS (diluted)$0.27+145%

Balance sheet

See full
Cash & equivalents$190.0M+20.9%
Total debt$9.0M-9.0%
Total equity$605.7M+32.4%
Total assets$825.3M+37.7%

Cash flow

See full
Operating cash flow$50.2M+125%
CapEx$161.0K+62.6%
Free cash flow$50.0M+125%

Valuation

See full
Market cap$4.58B+128%

Profitability

See full
Gross margin89.3%+3.5pp
Operating margin12.4%+10.2pp
Net margin9.7%+7.6pp
FCF margin21.8%+12.2pp

Returns & leverage

See full
Return on equity13.7%+11.3pp
Debt / equity0×0.0×
Current ratio3.8×+0.1×

Where this comes from

Calculated from Kiniksa Pharmaceuticals International, plc’s reported figures.

total debt/total assets=0×

Based on the most recent quarter.

The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kiniksa Pharmaceuticals International, plc's debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kiniksa Pharmaceuticals International, plc's debt-to-assets?
Kiniksa Pharmaceuticals International, plc (KNSA) reported debt-to-assets of 0× in Q1 2026.
How has Kiniksa Pharmaceuticals International, plc's debt-to-assets changed year-over-year?
Kiniksa Pharmaceuticals International, plc's debt-to-assets decreased by 33.9% year-over-year, from 0× to 0×.
What is the long-term trend for Kiniksa Pharmaceuticals International, plc's debt-to-assets?
Over 5 years (2020 to 2025), Kiniksa Pharmaceuticals International, plc's debt-to-assets has grown at a -9.1% compound annual growth rate (CAGR), from 0× to 0×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.